SCHEMBL2115251

SCHEMBL2115251

O=C(O)c1ccc(-c2ccnc(O)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 4/20 0.57
MAPK8 P45983 3/20 0.50
PIK3CG P48736 2/20 0.50
CAMKK2 Q96RR4 2/20 0.50
LOXL2 Q9Y4K0 1/20 0.50
GSK3B P49841 1/20 0.50
KMO O15229 1/20 0.50
MAP4K4 O95819 1/20 0.50
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 3/20 0.45
POLB P06746 2/20 0.45
GAA P10253 2/20 0.45
HTT P42858 1/20 0.45
MAPK10 P53779 1/20 0.44
CHEK1 O14757 1/20 0.44
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3812954 0.84 HSP90AA1 (0.62) CAMK2DMAPK8PIK3CGCAMKK2LOXL2
SCHEMBL7226376 0.81 KMO (0.57) CAMK2DMAPK8PIK3CGCAMKK2LOXL2
SCHEMBL4899395 0.81 CAMK2D (0.64) CAMK2DMAPK8PIK3CGCAMKK2GSK3B
SCHEMBL4900944 0.79 CAMK2D (0.62) CAMK2DMAPK8PIK3CGCAMKK2GSK3B
SCHEMBL592929 0.79 ADORA2A (0.64) CAMK2DMAPK8KDM4ERAB9AMAPK10
SCHEMBL4902003 0.78 MEN1 (0.69) CAMK2DMAPK8PIK3CGCAMKK2LOXL2
SCHEMBL4901594 0.78 MEN1 (0.69) CAMK2DMAPK8PIK3CGCAMKK2GSK3B
SCHEMBL4903116 0.78 MEN1 (0.69) CAMK2DMAPK8PIK3CGCAMKK2LOXL2
SCHEMBL4898606 0.78 MAP4K4 (0.75) CAMK2DKMOMAP4K4KDM4ERAB9A
SCHEMBL7231775 0.78 CAMK2D (0.54) CAMK2DMAPK8PIK3CGCAMKK2LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119591550-A Preparation method of molatinib and key intermediate 沈阳药科大学 2025-03-11 CN claimed
CN-119591550-A Preparation method of molatinib and key intermediate 沈阳药科大学 2025-03-11 CN disclosed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US disclosed
CN-102241680-A Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC 2011-11-16 CN disclosed
CN-101048408-B Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC 2011-07-06 CN disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US disclosed
CN-101048408-A Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2007-10-03 CN disclosed
EP-1807429-A2 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM, LLC (BM) 2007-07-18 EP disclosed
WO-2006047516-A2 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH CAMK2D 554/4885MAPK8 1315/4885PIK3CG 66/4885
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH CAMK2D 554/4885MAPK8 1315/4885PIK3CG 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.